Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD +2.51%21 Net-Net Working Capital is $0.19 as of Sep. 2025. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 27 Medical Distribution companies, Cellyan Biotechnology Co ranks better than 77.78% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Cellyan Biotechnology Co's Net-Net Working Capital for the quarter that ended in Sep. 2025 was $0.19.
The industry rank for Cellyan Biotechnology Co's Net-Net Working Capital or its related term are showing as below:
HKPD's Price-to-Net-Net-Working-Capital is ranked better than 77.78% of 27
companies
in the Medical Distribution industry
Industry Median: 6.92
vs HKPD: 2.20
Cellyan Biotechnology Co (NAS:HKPD) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Cellyan Biotechnology Co Net-Net Working Capital Related Terms
Cellyan Biotechnology Co Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Cellyan Biotechnology Co's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Net-Net Working Capital Chart
HKPD vs MEDS, COSM, SNYR: Net-Net Working Capital Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Price-to-Net-Net-Working-Capital vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.19 mean?
Cellyan Biotechnology Co (HKPD) has a Net-Net Working Capital of $0.19 as of Sep. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Cellyan Biotechnology Co According to the industry distribution chart, Cellyan Biotechnology Co ranks #6 out of 27 companies in the Medical Distribution industry, placing it in the top 22.2%.
Is Cellyan Biotechnology Co's Net-Net Working Capital too high?
Cellyan Biotechnology Co's current Net-Net Working Capital is $0.19. The Medical Distribution industry median Net-Net Working Capital is 6.92. Cellyan Biotechnology Co's value of $0.19 is 97.3% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #6 out of 27 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Net-Net Working Capital compare to MEDS and COSM?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #6 out of 27 companies for Net-Net Working Capital. This places Cellyan Biotechnology Co in the top 22% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.92. Cellyan Biotechnology Co's value of $0.19 is 97.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Distribution company?
The median Net-Net Working Capital among Medical Distribution companies is 6.92, based on 27 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Net-Net Working Capital of $0.19 is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Cellyan Biotechnology Co For the Medical Distribution industry, the median Net-Net Working Capital is 6.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Net-Net Working Capital is $0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Net-Net Working Capital of $0.19. The current Net-Net Working Capital is $0.19 and 97.3% below the Medical Distribution industry median of 6.92. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Net-Net Working Capital is $0.19 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
